Association of Cancer Care Centers’ Post

I presented three real-world evidence (RWE) abstracts mdanderson at #ESMO24. Those RWE identify unmet clinical needs and set bench marks for efficacy evaluation, which are critical initial steps for drug development. ESMO - European Society for Medical Oncology 👉 In the HER2 NSCLC RWE analysis (n=589), we found that most oncogenic mutations are in the HER2 kinase domain. The 1L therapy mPFS for those patients was only 5.5 months and OS 16.0 months, therefore, new targeted therapies are needed. Boehringer Ingelheim Bayer Gerrina Ruiter Dominik Ruettinger 👉 In the MET NSCLC RWE analysis (n=456), we found MET over expression (OE) occurs in 20-25% of NSCLC. MET OE high NSCLC patients had a significantly shorter time to next treatment (TTNT) than MET OE low/no patients, this identified a major unmet need to improve MET OE patient's outcome. AbbVie Olga Ryan 👉 In the EGFR uncommon mutation RWE analysis (n=3,276), many EGFR PACC mutation patients are still receiving chemo-IO with PFS only at 4.2 months, and osimertinib with PFS at 6.0 months, we need better precision oncology practice and designed TKI for EGFR PACC mutations. Dr. Elizabeth Buck Black Diamond Therapeutics Sergey Yurasov

We're excited to share the latest breakthrough from the DMA (Dutch Medication Audit) project, supported by DICA (Dutch Institute for Clinical Auditing), Nederlandse Vereniging van Ziekenhuisapothekers (NVZA), and Zorgverzekeraars Nederland! With the collaboration of 56 hospitals, DMA investigated whether proton pump inhibitors (PPIs) affect the effectiveness of CKD4/6 inhibitors in breast cancer treatment. The findings? No impact on overall survival was observed, putting into question the validity of concerns about reduced efficacy when PPIs are prescribed alongside CKD4/6 inhibitors. This milestone underscores the power of data sharing and collaborative discussions in advancing patient care, which are supported by MRDM and LOGEX with data processing and analysis. 📊✨ Together, we’re transforming real-world data into real-world solutions. Join us in our mission to enhance healthcare through evidence-based insights! 👉 Learn more about our work and how you can get involved: https://lnkd.in/eH6mZd5k #HealthcareInnovation #HealthcareAnalytics #DataDrivenCare #PatientCare #ClinicalInsights #Oncology #DataAnalytics

What an insightful few days for the Flatiron Health Germany team at #DGHO2024 - an incredibly important hematology and oncology conference in Germany! Our conversations with oncology clinics underscored a pressing challenge: care data is often underutilized and there is a huge need to unlock EHR data for research. In the German healthcare landscape, a variety of solutions and registries are emerging, each tailored to address specific challenges within oncology. These initiatives highlight the intricate nature of healthcare data and the critical need for collaboration. By embracing the idea that diverse Real-World Evidence (RWE) approaches can coexist and complement each other, we can harness the strengths of each system to improve patient care and enhance research outcomes. Let's improve #cancercare by learning from every patient's experience!

Free Patient Webinar from the National Comprehensive Cancer Network® (NCCN®) on Myeloproliferative Neoplasms (MPN) Tuesday, September 24, 2024 11:00 AM - Join experts as they discuss MPN, including polycythemia vera (PV), essential thrombocythemia (ET), and myelofibrosis (MF). This free webinar is designed to help participants: Understand their diagnosis; Engage in shared decision-making: Compare, discuss, and select medical treatment options with their care team, including how to access clinical trials; Learn about the role of a pharmacist in treating MPN and managing side effects; Gather tips for navigating patient and caregiver resources and insight into living with MPN. Register: https://ow.ly/tPyj50SELLJ

When patients choose community cancer care, they are receiving more personalized care. Patients prefer personalized care, but some leave the community setting to travel to academic centers with the thinking that academia can offer them more options treatment-wise. VieCure can bring the infrastructure needed to the community setting so patients can receive the latest treatment options without traveling away from home and their support systems. VieCure is equipped with all of the tools necessary to help physicians deliver standard-of-care, patient-centered precision oncology at the community level. Delivering quality cancer care can be challenging, it is difficult to stay up to date on new drugs, order diagnostics, select the right treatment plan, and be available for each patient promptly. VieCure understands these challenges and has developed a patient-centric ecosystem that supports and enables the physician to spend more time where it matters most, with the patient. #VieCure #PatientCenteredCare

Check out OneOncology's 2023 Annual Report online!

🎗️ Elevating Oncology Care Through Decentralized Clinical Trials 🎗️ As we honor Breast Cancer Awareness Month, it's vital to explore how Decentralized Clinical Trials (DCTs). These innovative trials could help redefine cancer care, making it more accessible and patient-friendly. Our tool, the eyesON Decentralized Clinical Trials Outlook, identifies untapped opportunities to expand DCTs in oncology based on three key factors: ▪ Oncology patients ▪ Registered oncologists ▪ Broadband internet coverage Broadband internet plays a crucial role in enabling remote participation, reducing barriers for patients in underserved areas. But it’s not just about the internet; DCTs also rely on local resources like home nursing and healthcare facilities. Oncologists are the backbone of these trials, providing essential expertise and patient care throughout the process. Unlocking the potential of DCTs could open new doors for cancer care, reaching more patients and improving outcomes. 👉 For more insights, check out our article: https://lnkd.in/dH7W4ZBD #ClinicalTrials #DCT #Oncology #CancerSurvivorship #InnovationInHealth #BreastCancerAwareness #Cyntegrity #RBQM

Have you seen our latest addition to our suite of digital solutions? We created a novel cancer management system called Pathpoint Oncology.🌟 What does it do? Pathpoint Oncology provides: ✅  a reliable, specialty-specific clinical workflow that helps improve collaboration across teams ✅ unmatched visibility of real-time patient progress and potential breaches ✅ automation to simplify and enhance the collection and reporting of data for national as well as local purposes ✅ standardised, efficient, and safe MDT workflows And that's just the tip of the iceberg. Click on the link below 👇 to explore how Pathpoint Oncology can help you. 🔗 https://lnkd.in/ezfJiUbu #oncology #cancercare #digitalsolutions #cancermanagementsystem #digitaltransformatioon #digitalhealth #healthtech #healthcare #technology

Want an in-depth education covering a range of immunotherapy topics? Register for sessions covering disease states and topics of your choosing in the 2024 Advances in Cancer Immunotherapy™ Series: sitcancer.org/aci where you will receive expert training and the latest in clinical data. Also, the sessions are free to healthcare professionals, students, patients, and patient advocates. Brought in collaboration with SITC and the Advanced Practitioner Society for Hematology and Oncology, this series is certified for CME, CNE, CPE, and MOC credits, this series aims to provide what health professionals need to know to make informed, confident decisions when integrating immunotherapy treatments into clinical practice. Register today: sitcancer.org/aci! #immunotherapy #breastcancer #TILTherapy #CME #CNE #CPE

📣 2023 was a break-out year for OneOncology, as our latest annual report showcases. 🥁 Inside our 2023 annual report, you'll learn about how we reached a $2.1 billion valuation in under 5 years. 📈 You'll read about the impressive growth OneOncology realized by adding practices to the platform, and by helping our partners grow their practices locally by adding physicians and services along the cancer care continuum. 🎯 The report details the clinical technology and innovation OneOncology has brought forward to make it easier for our physician partners to practice high-quality care. ⚙ And the report highlights the services we're centralizing to create efficiencies for our partners. 💬 As CEO Jeff Patton, MD writes in his opening letter: 2023 was a year of validation for OneOncology and our business model. ⤵ Click on the report to read it, and drop us a line with your thoughts. ⤵ https://lnkd.in/ebHp5Q9y